Matthias Gossel

This inventor holds 46 USPTO granted patents and 8 published patent applications and 18 EPO patents, primarily in GPR119 Modulators. Top assignees: Aventis Pharma Deutschland, Gmbh, Sanofi-A Ventis Deutschland Gmbh, Sanofi. Active years: 2002-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Gossel. Retrieved from https://idiyas.com/inventor/matthias-gossel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 46 (Patent Applications = 8)

% Patents Active = 47.8

EPO Patents = 18 (Patent Applications = 12)

Average Co-Inventor Count = 4.9

ph-index = 6

Forward Citations = 243(Granted Patents)

Location History:

Hofheim, DE (2002 - 2013)
Frankfurt-am-Main, DE (2010 - 2018)

Company Filing History:

18 out of 330

Aventis Pharma Deutschland, Gmbh

patents

17 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

where one patent can have more than one assignee

Years Active: 2002-2018

Loading Chart...

Areas of Expertise:

GPR119

Diabetes

Obesity

Heterocycles

Medicaments

Indanones

Amines

Dihydroisoquinolinones

Pyrimidines

Pharmaceuticals

Hexahydropyrazines

Aryl Compounds

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9908868 - Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-03-06),

2. 9896434 - Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-02-20),

3. 9758520 - Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2017-09-12),

4. 8853412 - Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2014-10-07),

5. 8853208 - Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments (2014-10-07),

6. 8841290 - Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs (2014-09-23),

7. 8828991 - Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments (2014-09-09),

8. 8822495 - Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments (2014-09-02),

9. 8609731 - Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments (2013-12-17),

10. 8586609 - Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament (2013-11-19),

11. 8552199 - Substituted indanes, method for the production thereof, and use thereof as drugs (2013-10-08),

12. 8501771 - Aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments (2013-08-06),

13. 8357686 - Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament (2013-01-22),

14. 8299104 - Aryl-substituted heterocycles, process for their preparation and their use as medicaments (2012-10-30),

15. 8163741 - Use of aryl-substituted polycyclic amines as medicaments (2012-04-24),

Title: Matthias Gossel - Innovator in Pharmaceutical Compounds

Introduction

Matthias Gossel is an eminent inventor based in Hofheim, Germany, recognized for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 46 patents, Gossel has been at the forefront of innovative research, focusing on compounds that address critical health issues such as diabetes and obesity.

Latest Patents

Gossel's latest inventions include two notable patents involving isoindolinone compounds and substituted indanone compounds. The first patent, titled "Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders," describes isoindolinone compounds that serve as GPR119 modulators. These compounds are useful for preventing and treating diabetes, obesity, dyslipidemia, and related disorders, as well as being integral active ingredients in pharmaceutical compositions. The second patent, "Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders," outlines similar applications for indanone compounds, emphasizing their potential impact on these health conditions.

Career Highlights

Throughout his career, Matthias Gossel has been associated with prominent organizations in the pharmaceutical industry. He worked at Aventis Pharma Deutschland GmbH and Sanofi-Aventis Deutschland GmbH, where he collaborated on numerous projects that further advanced his expertise and innovation in the field.

Collaborations

Gossel has had the privilege of working alongside distinguished colleagues, including Siegfried Stengelin and Lothar Schwink. Their collaborations have contributed to the successful development of various pharmaceutical compounds and innovations.

Conclusion

Matthias Gossel’s persistent commitment to medical research and innovation is evident through his extensive patent portfolio and collaborations in the pharmaceutical industry. His work continues to pave the way for advancements in treating critical health issues, showcasing the power of innovation in improving lives.

Profile summary based on public USPTO records.